Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study
2024 ASCO Annual Meeting
Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
ECHELON-3 was a Phase 3 double-blind placebo-controlled trial in patients with diffuse large B-cell lymphoma that had relapsed or refractory disease to prior therapy. In this study, they particularly enrolled those patients that were either ineligible for or had received prior treatment with both CAR-T cell therapy or hematopoietic stem cell transplant.
In this trial, investigators evaluated a combination of lenalidomide and rituximab with either brentuximab vedotin or placebo. It was a median of three prior therapies, and in general the patients were heavily pre-treated, including approximately half of patients having primary refractory disease, 30% of patients with prior CAR-T cell exposure, and approximately 15% of patients had prior bispecific antibody exposure.
We see with the combination of brentuximab vedotin, lenalidomide and rituximab, that this is a very active regimen, and we're seeing high complete response rates along with encouraging durability at this point. These improved responses were encouragingly seen in both CD30-positive and CD30-negative patients, and this translated into an improvement in progression-free along with overall survival.
And importantly, we saw some improvements in really key subsets of patients with high-risk features such as those with high IPI, those patients with prior CAR-T exposure, along with those patients with nongerminal center cell of origin, and this regimen though was not without its own toxicity, and we saw higher incidence of Grade 3 or greater adverse events in the [inaudible 00:01:40] and rituximab arm compared to lenalidomide-rituximab alone, particularly those manifested as hematologic toxicity, along with increased risk of peripheral neuropathy.
In general this was an active regimen, and is particularly encouraging for those patients that may not be either eligible for, or have previously received, therapy with things like bispecific antibodies, CAR-T or hematopoietic stem cell transplant.
This is currently an interim analysis, and we will need longer follow-up in order to have a better understanding of long-term outcomes, particularly in terms of both safety and efficacy.
The ASCO Post Staff
David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).
The ASCO Post Staff
Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.
The ASCO Post Staff
Jean-Marc Classe, MD, PhD, of France’s Nantes Université, discusses phase III results showing that systematic lymphadenectomy should be omitted in patients with advanced epithelial ovarian cancer with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery (LBA5505).
The ASCO Post Staff
Narjust Florez, MD, of the Dana-Farber Cancer Institute, and Suresh S. Ramalingam, MD, of Emory University School of Medicine, Winship Cancer Institute, discuss potentially practice-changing phase III results from the LAURA study. This trial showed that osimertinib after definitive chemoradiation therapy improved progression-free survival for patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC), suggesting this agent may represent a new standard of care in this setting (LBA4).
The ASCO Post Staff
Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).